Approximate Bayesian Bootstrap procedures to estimate multilevel treatment effects in observational studies with application to type 2 diabetes treatment regimens

Author:

Scotina Anthony D1ORCID,Zullo Andrew R2,Smith Robert J3,Gutman Roee4

Affiliation:

1. Division of Mathematics, Computing, and Statistics, Simmons University, Boston, MA, USA

2. Department of Health Services, Policy, and Practice, Brown University, Providence, RI, USA

3. Warren Alpert Medical School, Brown University, Providence, RI, USA

4. Department of Biostatistics, Brown University, Providence, RI, USA

Abstract

Randomized clinical trials are considered as the gold standard for estimating causal effects. Nevertheless, in studies that are aimed at examining adverse effects of interventions, randomized trials are often impractical because of ethical and financial considerations. In observational studies, matching on the generalized propensity scores was proposed as a possible solution to estimate the treatment effects of multiple interventions. However, the derivation of point and interval estimates for these matching procedures can become complex with non-continuous or censored outcomes. We propose a novel Approximate Bayesian Bootstrap algorithm that results in statistically valid point and interval estimates of the treatment effects with categorical outcomes. The procedure relies on the estimated generalized propensity scores and multiply imputes the unobserved potential outcomes for each unit. In addition, we describe a corresponding interpretable sensitivity analysis to examine the unconfoundedness assumption. We apply this approach to examine the cardiovascular safety of common, real-world anti-diabetic treatment regimens for type 2 diabetes mellitus in a large observational database.

Funder

Patient-Centered Outcomes Research Institute

Publisher

SAGE Publications

Subject

Health Information Management,Statistics and Probability,Epidemiology

Reference68 articles.

1. Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005

2. DEPARTMENT OF ERROR

3. Effects of Intensive Glucose Lowering in Type 2 Diabetes

4. FDA. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin, www.fda.gov/drugs/drug-safety-and-availability (2018, accessed 28 September 2019).

5. FDA. FDA proposes broad approach for conducting safety trials for type 2 diabetes medications, www.fda.gov/news-events/press-announcements/fda-proposes-broad-approach-conducting-safety-trials-type-2-diabetes-medications (2020, accessed 26 April 2020).

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3